COVID-19 Update

Healthcare institutions and laboratories are encouraged to exercise and continue to practice appropriate clinical precautions when handling breath samples from patients. These groups should refer to their own policies on how to handle its COVID-19 response and should respond appropriately as the COVID-19 situation applies to and impacts its breath testing in its facilities.

Judgement on whether or not to test a patient using the BreathTek® UBT for H. pylori Kit should continue to be made by the patient’s prescribing physician and in collaboration with local testing laboratories on an individual patient basis.

While the COVID-19 situation continues to be dynamic, Otsuka sources the components of the BreathTek® UBT in the United States and currently does not foresee disruptions to its supply.

April 202005US20EBP0007

Eradication Testing

H. pylori resistance is on the rise1

H. pylori eradication therapy fails in 1 out of 4 patients.2,3

  • Antibiotic resistance, poor compliance—or both—are considered the most common causes of H. pylori treatment failure4
    • Antibiotic resistance may be the strongest predictor of treatment failure5
    • Success rates with the PPI/amoxicillin/clarithromycin combination are in the "unacceptable range" (<80%) worldwide, including in the United States6

Confirm the cure: symptom resolution does not always mean success

step 1

Diagnose if H. pylori is the underlying issue1,7


Consider a guideline-recommended therapy for patients who test positive2,7


Wait 4 weeks to allow for any recolonization that may occur7,8


Test again after completing treatment to confirm successful eradication8,9

Confirmation of H. pylori eradication is recommended—generally with a noninvasive test for active infection.8

  • Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133(3):985-1001.
  • Vakil N, Fendrick AM. How to test for Helicobacter pylori in 2005. Cleve Clin J Med. 2005;72(suppl 2):S8-S13.
  • Chu Y-T, Wang Y-H, Wu J-J, Lei H-Y. Invasion and multiplication of Helicobacter pylori in gastric epithelial cells and implications for antibiotic resistance. Infect Immun. 2010;78(10):4157-4165.
  • Graham DY, Lee Y-C, Wu M-S. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12(2):177-186.
  • Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143-1153.
  • Graham DY, Shiotani A. Newer concepts regarding resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5(6):321-331.
  • Talley NJ; American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 2005;129(5):1753-1755.
  • Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-238.
  • Graham-Lomax K, Graham DY. Contemporary Diagnosis and Management of H. pylori-Associated Gastrointestinal Diseases. 3rd ed. Newtown, PA: Handbooks in Health Care Co; 2005.